Takeda to seek approval of plaque psoriasis pill on Phase III trial data
Takeda’s once-daily oral plaque psoriasis (PsO) drug has met all its endpoints in two pivotal trials, with the company set…
News
Eli Lilly’s oral GLP-1RA maintains weight loss from injectable drugs
Soligenix reports Phase IIa SGX945 trial data for Behçet’s disease
Qihan Biotech begins subject dosing in Phase I/IIa study of QT-019B for rSLE
Galderma’s Nemluvio shows itch reduction in 48 hours
Padcev-Keytruda notches another Phase III win in bladder cancer
Hutchmed begins Phase I HMPL-A251 clinical development programme
Northwell Health and START open early-phase cancer trial facility
